Titlebook: Biopharmaceutical Applied Statistics Symposium; Volume 2 Biostatisti Karl E. Peace,Ding-Geng Chen,Sandeep Menon Book 2018 Springer Nature S

涌出

書目名稱Biopharmaceutical Applied Statistics Symposium影響因子(影響力)




書目名稱Biopharmaceutical Applied Statistics Symposium影響因子(影響力)學(xué)科排名




書目名稱Biopharmaceutical Applied Statistics Symposium網(wǎng)絡(luò)公開度




書目名稱Biopharmaceutical Applied Statistics Symposium網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Biopharmaceutical Applied Statistics Symposium被引頻次




書目名稱Biopharmaceutical Applied Statistics Symposium被引頻次學(xué)科排名




書目名稱Biopharmaceutical Applied Statistics Symposium年度引用




書目名稱Biopharmaceutical Applied Statistics Symposium年度引用學(xué)科排名




書目名稱Biopharmaceutical Applied Statistics Symposium讀者反饋




書目名稱Biopharmaceutical Applied Statistics Symposium讀者反饋學(xué)科排名

Glower

Assignment

biosphere

Advancing Interpretation of Patient-Reported Outcomes,ion of the patient’s response by a clinician or anyone else. In this chapter methods of PRO interpretation are discussed, under the assumption that a PRO instrument has already evidenced validity and reliability, in order to lend meaning and import to PRO scores. Specifically, we focus on three ways

Kindle

maroon

革新

Missing Data,ore the end of a trial or a laboratory test that cannot be obtained. Depending on why and how much data are missing, the results and interpretability of the trial can be jeopardized. Fortunately, there is a vast literature about statistical methods that can handle missing data. Probably the most imp

Myelin

Bayesian Subgroup Analysis with Hierarchical Models,ion. To address this unwanted variation, we consider Bayesian hierarchical modeling of subgroups. When considered exchangeable in a one-way hierarchical structure, the subgroup treatment effects have posterior means that shrink the sample estimates toward the overall estimate. The amount of shrinkag

Commodious

,A Question-Based Approach to?the?Analysis of Safety Data,f focus in both the pre-marketing drug development and post-approval life cycle management phases. In the pre-market setting, the primary safety information comes from clinical trials data covering several domains and other supporting information, such as, safety pharmacology, toxicology, historical

sinoatrial-node